ASTELLAS PHARMA UNSP/ADR (ALPMY) analyst actions
Rating and price-target actions on ALPMY in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ALPMY overview →
2 measured ALPMY analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy | Press release | +0.00% | -0.16% | |
| Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan | Press release | +0.01% | -0.13% |
Keep exploring
More ALPMY: earnings → · SEC filings → · ALPMY overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Utah Medical Products, Inc. (UTMD) | 96 | 0.00% | 48% |
| Pieris Pharmaceuticals, Inc. (PIRS) | 95 | 0.00% | 39% |
| Check-Cap Ltd. - Ordinary Share (CHEK) | 94 | -0.11% | 42% |
| Titan Pharmaceuticals, Inc. (TTNP) | 94 | +0.47% | 61% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.